Molecular Insight Pharma Inc. (MIPI) reported one-year follow-up data from a Phase I dose-escalation clinical study of Azedra. The company said the study demonstrated a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers, pheochromocytoma and paraganglioma.
The study was designed to evaluate the safety and identify the maximum tolerated dose of Azedra, as well as to collect clinical data on efficacy. In the 12-month data reported, a single dose of Azedra was shown to be well tolerated by patients, and toxicities were predictable and manageable. Azedra demonstrated clinical benefit, stabilizing or reducing tumor volumes in a majority of patients.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.